Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 7.44
CVSI's Cash-to-Debt is ranked higher than
63% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. CVSI: 7.44 )
Ranked among companies with meaningful Cash-to-Debt only.
CVSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27  Med: 2.51 Max: No Debt
Current: 7.44
0.27
No Debt
Equity-to-Asset 0.81
CVSI's Equity-to-Asset is ranked higher than
77% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CVSI: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
CVSI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.8 Max: 0.99
Current: 0.81
-0.02
0.99
Debt-to-Equity 0.04
CVSI's Debt-to-Equity is ranked higher than
87% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. CVSI: 0.04 )
Ranked among companies with meaningful Debt-to-Equity only.
CVSI' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14  Med: 0.1 Max: 0.66
Current: 0.04
-0.14
0.66
Debt-to-EBITDA 0.22
CVSI's Debt-to-EBITDA is ranked higher than
88% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. CVSI: 0.22 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CVSI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.74  Med: -0.28 Max: 0.22
Current: 0.22
-4.74
0.22
Interest Coverage 10.46
CVSI's Interest Coverage is ranked lower than
70% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. CVSI: 10.46 )
Ranked among companies with meaningful Interest Coverage only.
CVSI' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 10.46
Current: 10.46
0
10.46
Piotroski F-Score: 8
Altman Z-Score: 48.73
Beneish M-Score: -0.90
WACC vs ROIC
18.11%
27.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 11.42
CVSI's Operating Margin % is ranked higher than
60% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. CVSI: 11.42 )
Ranked among companies with meaningful Operating Margin % only.
CVSI' s Operating Margin % Range Over the Past 10 Years
Min: -103.79  Med: -75.07 Max: 11.42
Current: 11.42
-103.79
11.42
Net Margin % 11.08
CVSI's Net Margin % is ranked higher than
69% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. CVSI: 11.08 )
Ranked among companies with meaningful Net Margin % only.
CVSI' s Net Margin % Range Over the Past 10 Years
Min: -127.85  Med: -106.11 Max: 11.08
Current: 11.08
-127.85
11.08
ROE % 21.51
CVSI's ROE % is ranked higher than
87% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. CVSI: 21.51 )
Ranked among companies with meaningful ROE % only.
CVSI' s ROE % Range Over the Past 10 Years
Min: -77.5  Med: -55.15 Max: 21.51
Current: 21.51
-77.5
21.51
ROA % 16.38
CVSI's ROA % is ranked higher than
92% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. CVSI: 16.38 )
Ranked among companies with meaningful ROA % only.
CVSI' s ROA % Range Over the Past 10 Years
Min: -3066.67  Med: -49.89 Max: 16.38
Current: 16.38
-3066.67
16.38
ROC (Joel Greenblatt) % 59.29
CVSI's ROC (Joel Greenblatt) % is ranked higher than
91% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. CVSI: 59.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -148.17  Med: -82.49 Max: 59.29
Current: 59.29
-148.17
59.29
3-Year Revenue Growth Rate -7.30
CVSI's 3-Year Revenue Growth Rate is ranked lower than
84% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. CVSI: -7.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVSI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.65 Max: -1.2
Current: -7.3
3-Year EPS without NRI Growth Rate -14.50
CVSI's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. CVSI: -14.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVSI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -227.1  Med: -36.6 Max: -5.5
Current: -14.5
-227.1
-5.5
GuruFocus has detected 5 Warning Signs with CV Sciences Inc CVSI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVSI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

Latest Guru Trades with OTCPK:CVSI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 2833
Compare:OTCPK:ELTP, LSE:SIS, HKSE:01498, XKRX:900120, XKRX:018620, BOM:530199, TSX:CPH, NAS:ACET, XCNQ:GLH, ROCO:4191, ROCO:6562, OTCPK:COSM, XKLS:7213, KAR:MACTER, HKSE:00503, ROCO:1796, XCNQ:HIKU, XCNQ:EAT, ROCO:4168, NAS:MEIP » details
Traded in other countries:0VE.Germany,
Headquarter Location:USA
CV Sciences Inc is a life science company. It operates two business segments specialty pharmaceutical and consumer product.

CV Sciences Inc is a life science company. It operates two business segments specialty pharmaceutical and consumer product. Pharmaceutical segment is focused on developing and commercializing novel therapeutics utilizing synthetic CBD. Consumer product segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. Currently distributed nationally in health food stores, health care provider's offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician's recommendations.

Top Ranked Articles about CV Sciences Inc

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CV Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline- CVSI
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CV Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline– CVSI
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CV Sciences, Inc. (Other OTC: CVSI) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
CV Sciences, Inc. Achieves Industry’s First Hemp Extract GRAS Self-Affirmation
CV SCIENCES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In CV Sciences, Inc. To Contact The Firm
Investor Alert: Kaplan Fox Announces Investigation Of CV Sciences, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CV Sciences, Inc. - CVSI
CV Sciences, Inc. to Present and Exhibit as Gold Sponsor at Natural Products Expo East 2018 in Baltimore, Maryland, September 12-15, 2018
RM LAW Announces Class Action Lawsuit Against CV Sciences, Inc.
CV Sciences, Inc. provides corporate update to shareholders

Ratios

vs
industry
vs
history
PE Ratio 134.50
CVSI's PE Ratio is ranked lower than
93% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. CVSI: 134.50 )
Ranked among companies with meaningful PE Ratio only.
CVSI' s PE Ratio Range Over the Past 10 Years
Min: 40.75  Med: 120.69 Max: 408.16
Current: 134.5
40.75
408.16
PE Ratio without NRI 134.50
CVSI's PE Ratio without NRI is ranked lower than
92% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. CVSI: 134.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVSI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 40.75  Med: 120.69 Max: 408.16
Current: 134.5
40.75
408.16
Price-to-Owner-Earnings 114.47
CVSI's Price-to-Owner-Earnings is ranked lower than
88% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. CVSI: 114.47 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVSI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 31.54  Med: 45.53 Max: 140.64
Current: 114.47
31.54
140.64
PB Ratio 22.42
CVSI's PB Ratio is ranked lower than
96% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. CVSI: 22.42 )
Ranked among companies with meaningful PB Ratio only.
CVSI' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 2.27 Max: 275.93
Current: 22.42
0.23
275.93
PS Ratio 15.97
CVSI's PS Ratio is ranked lower than
83% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CVSI: 15.97 )
Ranked among companies with meaningful PS Ratio only.
CVSI' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 3.63 Max: 665.48
Current: 15.97
0.36
665.48
Price-to-Free-Cash-Flow 62.56
CVSI's Price-to-Free-Cash-Flow is ranked lower than
69% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. CVSI: 62.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVSI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.25  Med: 13.39 Max: 76.86
Current: 62.56
6.25
76.86
Price-to-Operating-Cash-Flow 61.14
CVSI's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. CVSI: 61.14 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVSI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.25  Med: 13.16 Max: 75.11
Current: 61.14
6.25
75.11
EV-to-EBIT 134.13
CVSI's EV-to-EBIT is ranked lower than
96% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. CVSI: 134.13 )
Ranked among companies with meaningful EV-to-EBIT only.
CVSI' s EV-to-EBIT Range Over the Past 10 Years
Min: -1454.1  Med: -1.9 Max: 522.9
Current: 134.13
-1454.1
522.9
EV-to-EBITDA 123.06
CVSI's EV-to-EBITDA is ranked lower than
95% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. CVSI: 123.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVSI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2428  Med: -1.7 Max: 1744.4
Current: 123.06
-2428
1744.4
EV-to-Revenue 14.57
CVSI's EV-to-Revenue is ranked lower than
80% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. CVSI: 14.57 )
Ranked among companies with meaningful EV-to-Revenue only.
CVSI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 3.7 Max: 1065.3
Current: 14.57
0.4
1065.3
Current Ratio 4.73
CVSI's Current Ratio is ranked higher than
75% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. CVSI: 4.73 )
Ranked among companies with meaningful Current Ratio only.
CVSI' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.83 Max: 58.64
Current: 4.73
0.02
58.64
Quick Ratio 3.52
CVSI's Quick Ratio is ranked higher than
71% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. CVSI: 3.52 )
Ranked among companies with meaningful Quick Ratio only.
CVSI' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.24 Max: 49.78
Current: 3.52
0.02
49.78
Days Inventory 130.00
CVSI's Days Inventory is ranked lower than
56% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. CVSI: 130.00 )
Ranked among companies with meaningful Days Inventory only.
CVSI' s Days Inventory Range Over the Past 10 Years
Min: 130  Med: 588.18 Max: 981.35
Current: 130
130
981.35
Days Sales Outstanding 28.40
CVSI's Days Sales Outstanding is ranked higher than
89% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. CVSI: 28.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVSI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.1  Med: 26.62 Max: 242.32
Current: 28.4
10.1
242.32
Days Payable 24.72
CVSI's Days Payable is ranked lower than
89% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. CVSI: 24.72 )
Ranked among companies with meaningful Days Payable only.
CVSI' s Days Payable Range Over the Past 10 Years
Min: 10.37  Med: 45.43 Max: 50.13
Current: 24.72
10.37
50.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -39.40
CVSI's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. CVSI: -39.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVSI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86.6  Med: -61.5 Max: -39.4
Current: -39.4
-86.6
-39.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 538.00
CVSI's Price-to-Net-Cash is ranked lower than
97% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. CVSI: 538.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CVSI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 21.69  Med: 51.6 Max: 610
Current: 538
21.69
610
Price-to-Net-Current-Asset-Value 53.80
CVSI's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. CVSI: 53.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CVSI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.86  Med: 5.64 Max: 203.57
Current: 53.8
0.86
203.57
Price-to-Tangible-Book 31.65
CVSI's Price-to-Tangible-Book is ranked lower than
96% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. CVSI: 31.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CVSI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 3.97 Max: 143.22
Current: 31.65
0.84
143.22
Price-to-Intrinsic-Value-Projected-FCF 269.00
CVSI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
100% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. CVSI: 269.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVSI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 83  Med: 83 Max: 305
Current: 269
83
305
Price-to-Median-PS-Value 4.41
CVSI's Price-to-Median-PS-Value is ranked lower than
95% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. CVSI: 4.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVSI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.93 Max: 63.93
Current: 4.41
0.2
63.93
Price-to-Graham-Number 13.79
CVSI's Price-to-Graham-Number is ranked lower than
98% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. CVSI: 13.79 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CVSI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.81  Med: 4.04 Max: 15.64
Current: 13.79
3.81
15.64
Earnings Yield (Greenblatt) % 0.76
CVSI's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. CVSI: 0.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVSI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -232.6  Med: -7.9 Max: 9.2
Current: 0.76
-232.6
9.2

More Statistics

Revenue (TTM) (Mil) $33.25
EPS (TTM) $ 0.04
Beta2.52
Volatility194.86%
52-Week Range $0.14 - 9.20
Shares Outstanding (Mil)90.95

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}